TOP TEN perturbations for Q9C0G0 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9C0G0
Selected probe(set): 227768_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9C0G0 (227768_at) across 5880 perturbations tested by GENEVESTIGATOR:

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.8490553
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

zalypsis study 1 / untreated MM1S cell sample

Relative Expression (log2-ratio):-2.7821655
Number of Samples:2 / 2
Experimental zalypsis study 1
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated MM1S cell sample
MM1S multiple myeloma cells untreated.

plicamycin study 2 (100 nM) / vehicle (PBS) treated TC-71 cell sample

Relative Expression (log2-ratio):-2.2070847
Number of Samples:3 / 3
Experimental plicamycin study 2 (100 nM)
TC-71 Ewing´s sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code:
Control vehicle (PBS) treated TC-71 cell sample
TC-71 Ewing´s sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours.

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):2.1064072
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

CAR T cell study 4 (PSCA-28t28Z; pre-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-1.988615
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):1.8948584
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):1.8663855
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

formaldehyde study 6 (100µM) / untreated TK6 cell sample

Relative Expression (log2-ratio):-1.8113413
Number of Samples:3 / 15
Experimental formaldehyde study 6 (100µM)
TK6 cells treated with 100µM formaldehyde for 4h. ATC code:---
Control untreated TK6 cell sample
Untreated TK6 cell line. Cells where left untreated for 4h before harvesting.

CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)

Relative Expression (log2-ratio):1.7735176
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

cisplatin study 4 (20uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):-1.7587633
Number of Samples:3 / 12
Experimental cisplatin study 4 (20uM)
HepG2 cells treated with compound: cisplatin (20uM; CAS no.:15663-27-1) for 24 hours. Cisplatin is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.